We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




New Gene Mutations Found for Wilms Tumor

By LabMedica International staff writers
Posted on 18 Sep 2014
Print article
Agilent\'s 2100 bioanalyzer system
The Agilent 2100 bioanalyzer system (Photo courtesy of AGILENT)
The genetic causes of Wilms tumor, a type of kidney cancer found only in children, has been revealed by whole-exome sequencing identifying missense mutations in the microRNA (miRNA)-processing enzymes.

Wilms tumor or nephroblastoma is the most common childhood genitourinary tract cancer and the third most common pediatric solid tumor and it comprises 95% of all renal cancers and 6% of all cancers diagnosed among children less than 15 years of age.

Scientists the University of Texas Southwestern Medical Center (Dallas, TX, USA) performed exome capture and massively parallel sequencing on a discovery set of 15 pairs of Wilms tumors and matched adjacent normal kidney cortices, and subsequently performed whole-exome sequencing on a validation set of 29 additional Wilms tumors. The team of scientists also performed cell culture and immunoprecipitation, small ribonucleic acid (RNA) sequencing.
.
Small RNAs were isolated from each tumor sample and all samples were analyzed using the RNA 6000 Nano LabChip (Agilent Technologies; Santa Clara, CA, USA) on an Agilent Technologies 2100 Bioanalyzer. Western blotting was performed using monoclonal antibodies and miRNA expression was analyzed in engineered cell lines. Libraries produced were sequenced using the HiSeq 2000 (Illumina; San Diego, CA, USA), producing 100 bp paired-end reads.

Examination of tumor miRNA expression, in vitro processing assays and genomic editing in human cells demonstrated that the gene mutations in endoribonuclease Dicer (DICER1) and ribonuclease 3 (DROSHA) influence miRNA processing through distinct mechanisms.

James F. Amatruda, MD, PhD, a Professor of Pediatrics, Molecular Biology, and Internal Medicine, and senior author of the study said, “The most common, and in some ways the most biologically interesting, mutations were found in genes called DROSHA and DICER1. We found that these mutations affected the cell's production of microRNAs, which are tiny RNA molecules that play big roles in controlling the growth of cells, and the primary effect was on a family of microRNAs called let-7. Let-7 is an important microRNA that slows cell growth and in Wilms tumors in which DROSHA or DICER1 were mutated, let-7 RNA is missing, which causes the cells to grow abnormally fast.” The study was published on September 5, 2014, in the journal Nature Communications.

Related Links:

University of Texas Southwestern Medical Center
Agilent Technologies 
Illumina 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.